• PRODUCTS
    • Assay Kit Platform & Formats
    • Reporter Assays By Receptor
    • Growth Factor Assays
    • Toxicology Kits
      • In Vitro Hepatotoxicity Assay Kit & Screening Services
      • Assay Kits & Services for Gene Expression Profiling
      • Human P-Glycoprotein / MDR1 Drug Interaction Assay Kit & Screening Services
    • Environmental Monitoring Assays
    • Animal Model Assays
    • INDIGlo Luciferase Detection Reagent
    • Live Cell Multiplex
  • SERVICES
    • Reporter Assay Services
    • Nuclear Receptor Profiling & Panels
    • Custom Assay Development
    • Environmental Testing Assays
    • Toxicology in The Drug Discovery and Development Process
  • RESOURCES
    • Nuclear Receptor Overview
    • Disease State Targets
      • Overview
      • Anemia & Kidney Disease
      • Autoimmune Disease & Inflammation
      • Cancer
      • Cardiovascular Disease
      • Diabetes
      • Endocrinology
      • NAFLD/NASH
      • Obesity
    • Articles, Blogs, and Posters
      • New Research Publications
      • Scientific Whitepapers from INDIGO
      • Scientific Posters from INDIGO
      • BLOG
    • Product Literature
      • INDIGO Technical Manuals
      • Product Material Safety Data Sheets
      • upcyte® Hepatocytes
    • FAQ
  • ABOUT
    • About INDIGO
    • Why INDIGO
    • Key Personnel
      • Board of Directors & Advisors
      • Management
    • Employment
    • INDIGO Press Releases
    • INDIGO in the News
  • CONTACT US
    • Contact INDIGO
    • Request a Quote
    • Ordering & Distributors
Search site...

± α β γ δ Δ ε ζ κ ω ö ® ™ µ

  • PRODUCTS
    • Assay Kit Platform & Formats
    • Reporter Assays By Receptor
    • Growth Factor Assays
    • Toxicology Kits
      • In Vitro Hepatotoxicity Assay Kit & Screening Services
      • Assay Kits & Services for Gene Expression Profiling
      • Human P-Glycoprotein / MDR1 Drug Interaction Assay Kit & Screening Services
    • Environmental Monitoring Assays
    • Animal Model Assays
    • INDIGlo Luciferase Detection Reagent
    • Live Cell Multiplex
  • SERVICES
    • Reporter Assay Services
    • Nuclear Receptor Profiling & Panels
    • Custom Assay Development
    • Environmental Testing Assays
    • Toxicology in The Drug Discovery and Development Process
  • RESOURCES
    • Nuclear Receptor Overview
    • Disease State Targets
      • Overview
      • Anemia & Kidney Disease
      • Autoimmune Disease & Inflammation
      • Cancer
      • Cardiovascular Disease
      • Diabetes
      • Endocrinology
      • NAFLD/NASH
      • Obesity
    • Articles, Blogs, and Posters
      • New Research Publications
      • Scientific Whitepapers from INDIGO
      • Scientific Posters from INDIGO
      • BLOG
    • Product Literature
      • INDIGO Technical Manuals
      • Product Material Safety Data Sheets
      • upcyte® Hepatocytes
    • FAQ
  • ABOUT
    • About INDIGO
    • Why INDIGO
    • Key Personnel
      • Board of Directors & Advisors
      • Management
    • Employment
    • INDIGO Press Releases
    • INDIGO in the News
  • CONTACT US
    • Contact INDIGO
    • Request a Quote
    • Ordering & Distributors

Related Articles: FXR

Print Friendly, PDF & Email

Discovery, optimization, and evaluation of non-bile acid FXR/TGR5 dual agonists

ABSTRACT Although several potent bile acid Farnesoid X receptor (FXR) and Takeda G-protein-coupled receptor 5 (TGR5, GPBAR1) dual agonists such as INT-767 have been reported, no non-bile acid FXR/TGR5 dual agonist has been investigated to date. Therefore, we attempted to discover potent non-bile acid FXR/TGR5 dual agonists and identified some non-bile acid FXR/TGR5 dual agonists,Read More

Posted in New Publications | Tagged farnesoid X receptor, FXR, NAFLD, NASH, Type 2 diabetes | Comments Off on Discovery, optimization, and evaluation of non-bile acid FXR/TGR5 dual agonists

COMPOSITIONS AND METHODS FOR TREATING CHOLESTATIC DISEASE

ABSTRACT The invention provides compositions and methods for use in the treatment and prevention of cholestatic diseases. To read the full Patent, click HERE. Date of publication: 14 January 2021; United States Patent Application 20210008128 Inventor Information: Nandakumar, Madhumitha (Arlington, MA, US), Liou, Alice Peiyu (Somerville, MA, US), Halvorsen, Elizabeth Moritz (Malden, MA, US), Mckenzie,Read More

Posted in New Publications | Tagged farnesoid X receptor, FXR | Comments Off on COMPOSITIONS AND METHODS FOR TREATING CHOLESTATIC DISEASE

Bacterial metabolism of bile acids promotes generation of peripheral regulatory T cells

ABSTRACT Intestinal health relies on the immunosuppressive activity of CD4+ regulatory T (Treg) cells. Expression of the transcription factor Foxp3 defines this lineage, and can be induced extrathymically by dietary or commensal-derived antigens in a process assisted by a Foxp3 enhancer known as conserved non-coding sequence 1 (CNS1). Products of microbial fermentation including butyrate facilitate the generationRead More

Posted in New Publications | Tagged bile acids, farnesoid X receptor, FXR, RORγt, T cells | Comments Off on Bacterial metabolism of bile acids promotes generation of peripheral regulatory T cells

Characterization of EDP-305, a Highly Potent and Selective Farnesoid X Receptor Agonist, for the Treatment of Non-alcoholic Steatohepatitis

ABSTRACT Non-alcoholic steatohepatitis (NASH), characterized by hepatocyte injury, inflammation, and fibrosis, is the maincause of chronic liver disease in the Western world. There are currently no approved pharmacological therapies for NASH, underscoring the urgent need for effective treatments. The farnesoid X receptor (FXR) has emerged as an attractive target for the treatment of metabolic andRead More

Posted in New Publications | Tagged agonist, Anti-fibrotic, Anti-inflammatory, Anti-steatosis, Bile Acid, FXR, Low Density Lipoprotein Receptor, NASH | Comments Off on Characterization of EDP-305, a Highly Potent and Selective Farnesoid X Receptor Agonist, for the Treatment of Non-alcoholic Steatohepatitis

Profiling Drug Activity of Human and Ortholog Xenobiotic-Sensing Receptors: PXR, CAR, AhR, and FXR

View Full Size Research conducted by: Koji Toyokawa (1), Ewa Maddox (1), Jack Vanden Huevel (1,2), & Bruce Sherf (1) (1) INDIGO Biosciences, Inc., 1981 Pine Hall Rd, State College, PA, USA (2) Center for Molecular Toxicology and Carcinogenesis, 325 Life Sciences Building, Penn State University, University Park, PA 16802, USA Date of Publication: 2017

Posted in New Publications, Posters | Tagged AhR, CAR, drug activity, FXR, ortholog, PXR, SOT 2017 | Comments Off on Profiling Drug Activity of Human and Ortholog Xenobiotic-Sensing Receptors: PXR, CAR, AhR, and FXR

Differential modulation of FXR activity by chlorophacinone and ivermectin analogs

ABSTRACT Chemicals that alter normal function of farnesoid X receptor (FXR) have been shown to affect the homeostasis of bile acids, glucose, and lipids. Several structural classes of environmental chemicals and drugs that modulated FXR transactivation were previously identified by quantitative high-throughput screening (qHTS) of the Tox21 10 K chemical collection. In the present study, weRead More

Posted in New Publications | Tagged CAR, FXR, LXR, LXRα | Comments Off on Differential modulation of FXR activity by chlorophacinone and ivermectin analogs

Effects of Munitions Compounds on Xenobiotic-Activated Nuclear Receptors and Signaling Pathways

ABSTRACT Exposure to certain munitions compounds is know to alter physiological functions in test organisms, however little is known about their molecular and cellular effects. Several nuclear receptors are regulated by xenobiotic compounds. These nuclear receptors belong to a class of ligand-activated transcription factors that, when heterodimerized with RXRa and bound to their respective DNARead More

Posted in New Publications | Tagged CAR, FXR, LXR, PPAR | Comments Off on Effects of Munitions Compounds on Xenobiotic-Activated Nuclear Receptors and Signaling Pathways

INDIGO Offers Expansion of Industry-Leading FXR Assay

Meets industry demand for increased pre-clinical predictability. State College, PA (August 9, 2016) INDIGO Biosciences, the recognized industry leader in Nuclear Receptor research, announced the addition of the Mouse Farnesoid X Receptor (mFXR) assay to their FXR portfolio. This addition both complements INDIGO’s industry-leading human FXR assay and meets the demand for an expansion ofRead More

Posted in press | Tagged FXR | Comments Off on INDIGO Offers Expansion of Industry-Leading FXR Assay

Oxysterols are agonist ligands of RORγt and drive Th17 cell differentiation

ABSTRACT The RAR-related orphan receptor gamma t (RORγt) is a nuclear receptor required for generating IL-17–producing CD4+ Th17 T cells, which are essential in host defense and may play key pathogenic roles in autoimmune diseases. Oxysterols elicit profound effects on immune and inflammatory responses as well as on cholesterol and lipid metabolism. Here, we describe the identification of several naturally occurringRead More

Posted in New Publications | Tagged CAR, er, FXR, GR, PPAR, PPARα, PPARβ, PPARγ, ROR, RORγ, RORγt | Comments Off on Oxysterols are agonist ligands of RORγt and drive Th17 cell differentiation

Activation of farnesoid-X-receptor (FXR) by bioactive lipids

View Full Size Research conducted by: Jerry Thompson (1), Jun Zhang (1), & Jack Vanden Huevel (1,2) (1) Center for Nutrigenomics, Penn State University, University Park, PA 16802, USA (2) INDIGO Biosciences, Inc., 1981 Pine Hall Rd, State College, PA, USA Date of Publication: March 2010

Posted in New Publications, Posters | Tagged FXR | Comments Off on Activation of farnesoid-X-receptor (FXR) by bioactive lipids
Request a Quote

Search

Search site...
Click to Insert Symbols in Search

α β γ δ Δ ε ζ κ ® ™ µ

Want More Information?

Resource Quick Links

  • Technical Manuals & Product Listing
  • Safety Data Sheets
  • Sample Study Report
  • Study Work Order Form

3006 Research Drive, Suite A1, State College, PA, USA 16801

+1 (814) 234-1919

  • Terms Conditions
  • Privacy Policy
  • Product Policies
  • Limited Use Disclosure

© 2022 INDIGO Biosciences, Inc. All Rights Reserved